Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: Great tweets of science
. I’m still on vacation, but I’m thinking about you loyal readers. I hope this clever list of tweets, from PhD Comics, gives you a chuckle. If you’re feeling creative, please add some additional “great tweets of science” in the comments below. Our regular feature, Right Turn, appears every Friday and we invite you […]
Right Turn: Vacation Relaxation
. I knew I was going to miss my co-editor, Lisa Willemse, but never more so than now, as I contemplate producing content for Signals during my three-week (spoiled, I know) vacation. The empathetic minds behind PhD Comics have neatly summed up my mood right now – and possibly yours too? Nevertheless, I’m excited; how ‘bout […]
Right Turn: Scaling up blood stem cells for transplants
. Cord blood banking is a growing market in North America and globally. Between 2005 and 2013, the number of privately banked units grew steadily at a CAGR (compound annual growth rate) of 25 per cent, giving companies the ability to capitalize on a part of the anatomy – the umbilical cord – that has […]
Right Turn: Moving RM discoveries to the market, in Ontario
.Today is a big day for the regenerative medicine (RM) community in Ontario, Canada. Minister of Research and Innovation, Reza Moridi, just announced that the Ontario Institute for Regenerative Medicine (OIRM) will receive a new $25 million commitment* (in addition to the $3.1 million committed in November 2014) to invest in translational research for degenerative […]
Comments